Estradiol + Norethindrone Acetate: The Definitive Guide

What is estradiol with norethindrone acetate?

Activella is a US oral fixed combination of estradiol, an estrogen, and norethindrone acetate, a synthetic progestin. It treats specified menopausal symptoms in a woman with a uterus and also has a restricted osteoporosis-prevention indication. The progestin is included to oppose estrogen’s effect on the uterine lining under the complete regimen. It is not micronized progesterone or an estrogen-only tablet. [1]

The checked UK product Kliovance contains the same named hormone pair at its specified strength, but its population, switching, missed-dose and storage instructions come from the UK SmPC. Norethindrone is called norethisterone in UK terminology. Similar ingredients and brand spelling do not establish interchangeable package instructions or current stock. [1], [2]

This is menopausal treatment, not an approved contraceptive schedule. An ethinyl-estradiol/norethindrone birth-control pill is another complete medicine. The guide verifies selected US/UK labels, not every brand or all-country availability. [1], [2], [3]

What are the exact continuous schedules?

Read both component amounts. The US 0.5 mg/0.1 mg tablet is not half of the 1 mg/0.5 mg pair: doubling the estrogen does not simply double the progestin. That is arithmetic about composition, not a prescription for replacing one with multiple lower-strength tablets. Choose the named complete tablet under the clinician’s plan. [1]

Activella’s US vasomotor instruction permits either listed strength, while its vaginal-atrophy instruction uses 1 mg/0.5 mg. Kliovance is one uninterrupted daily tablet; its SmPC says a higher-dose combination can be considered if relief is insufficient after three months. That is UK product guidance, not permission to add an estrogen tablet or override contraindications. [1], [2]

Evidence note: complete named US/UK labels. No hormone-free week, contraceptive calendar or dose-equivalence conversion is added.

Which symptoms and bone goals fit the labels?

Moderate-to-severe hot flashes are a direct treatment goal. Relief of night sweats can improve sleep when sweating interrupts it; a combination tablet does not treat every cause of insomnia, fatigue or low mood. Decide which symptom should change and what improvement would justify continuing, rather than judge treatment by a vague hormone-balance promise. [1], [2], [3]

The US product also treats moderate-to-severe vulvar/vaginal atrophy, with advice to consider topical vaginal treatment when that is the only goal. Its bone-prevention indication is limited: consider non-estrogen options first and estrogen only for significant osteoporosis risk. UK bone prevention is for high fracture risk with intolerance or contraindication to other approved preventive treatments. Those are not identical unrestricted bone-treatment indications. [1], [2]

How do missed tablets and switches differ?

Swallow the complete tablet under its leaflet, at a consistent time. The US patient leaflet says take a missed dose when remembered unless the next is almost due; do not take two together. UK Kliovance says take a forgotten tablet within the next 12 hours, otherwise discard it; missed tablets can increase spotting. Neither is a birth-control catch-up rule. [1], [2]

The UK switch from sequential HRT begins just after withdrawal bleeding has ended. This differs from some other combinations that start the day after the previous regimen ends. Keep the exact source-defined transition, especially if treatment is changing because of bleeding. A switch should also review contraception when pregnancy remains possible and any additional vaginal treatment. [2], [3]

How strong is the product evidence?

The US label describes placebo-controlled hot-flash studies and endometrial studies of the complete combination. Estradiol supplies systemic symptom treatment; the progestin reduces unopposed stimulation of the lining. This supports the named regimen, not every possible amount of separately added estradiol or a custom cream substitution. Included progestin is meaningful but not a guarantee against all uterine disease. [1], [2]

WHI tested oral CEE with or without medroxyprogesterone acetate, not Activella compared directly with a patch or Bijuva. Its class safety relevance should not become a precise risk estimate for these tablets. Likewise, a head-to-head long-term breast or cardiovascular advantage over every other progestogen was not verified here. Mechanism and individual preference are different from clinical-outcome superiority. [1], [2], [3], [4]

What risks and medicine interactions need review?

The checked contraindications include unexplained bleeding, breast or estrogen-dependent cancer, current or previous venous or arterial thromboembolic disease, relevant thrombophilia, liver disease and serious allergy. New severe headache, visual change or worsening symptoms deserve assessment. Sudden chest pain, breathlessness, a swollen painful leg, weakness or speech difficulty needs urgent assessment. A tablet’s included progestin does not override these risks. [1], [2]

Breast discomfort, headache, nausea, bleeding and mood or gastrointestinal changes can occur. Tell the clinician which started after treatment and which predated it; symptoms alone do not identify the estrogen or progestin as the cause. CYP3A4 inducers or inhibitors, including relevant herbal products, can affect exposure. Thyroid-replacement treatment may need monitoring because estrogen affects thyroid-binding proteins. [1], [2]

The current repository Activella label retrieved remains revised November 2023. FDA’s February 2026 first-six MHT approval announcement does not prove an Activella revision or removal of every risk. Kliovance’s own UK wording remains separate from US regulatory changes. [1], [2], [5]

What should follow-up include?

Record the exact pair of strengths, continuous calendar, missed tablets, hot flashes, sleep, bleeding and adverse effects. Review practical adherence before assuming the dose is insufficient. NICE recommends review at three months then annually, sooner for problems; UK Kliovance’s three-month response reassessment is a product-specific adjustment decision within that clinical process. [1], [2], [3]

Persistent unscheduled systemic-HRT bleeding beyond six months after starting or three months after a change needs prompt assessment under NICE, with earlier assessment when concerning. A continuous regimen aims for a different bleeding pattern from a planned sequential withdrawal bleed. Routine ultrasound or a serum estradiol target is not a substitute for assessing symptoms, history and correct use. Screening and tests should fit clinical need. [1], [2], [3]

How should you stop or change the fixed combination?

NICE allows gradual reduction or immediate stopping of MHT. With a fixed tablet, changing use changes both components together; do not assume that splitting or skipping alternate days preserves the tested regimen. Symptoms can return, and local vaginal therapy may remain useful after systemic treatment ends. [1], [2], [3]

If moving to separate estrogen and progestogen, define both schedules before the change. If systemic estrogen continues, required protection cannot simply be dropped. A switch should state the reason, new product, calendar and review plan, while serious suspected reactions need prompt assessment rather than an ordinary taper. [1], [2], [3]

How do US and UK storage rules differ?

US Activella is kept dry and protected from light at 20–25°C, with excursions permitted to 15–30°C. UK Kliovance says not above 25°C, do not refrigerate and keep the container in its outer carton for light protection. Retain the package and expiry; a foreign brand’s instruction does not replace the actual leaflet. Ask the pharmacist about damaged, overheated or uncertain medicine and use local disposal advice. [1], [2]

How does it compare with separate estradiol and progesterone?

A fixed tablet can simplify daily use but limits independent adjustment of estrogen and progestin. Separate components can permit a transdermal estrogen route or a different continuous/sequential plan, each needing its own protection evidence. Micronized progesterone differs from norethindrone acetate; preferences about sleep, mood or convenience do not supply a universal winner. [1], [2], [3]

Compare complete regimens: indication, route, estrogen exposure, progestogen, bleeding, contraindications and ability to use the plan reliably. Adding estrogen to a fixed tablet creates a new protection question. A low-dose local vaginal product for persistent GSM is a separate decision and does not replace protection required for the systemic regimen. [1], [2], [3]

What do public accounts describe?

The retrieved Activella page includes perceived hot-flash and sleep improvement and preference for continuing, alongside partial benefit, breast discomfort, headaches and emotional or gastrointestinal complaints. Some writers use different country brand names. These are full-combination accounts, not a way to isolate norethindrone or quantify current satisfaction. [6]

No ratings, identities, doses or response timelines are reproduced. Reports of recurrence after stopping help identify a follow-up question, but do not prove dependence or indefinite necessity. A story that one brand worked better than another cannot establish differences in potency or manufacturing quality without checking the actual products. [1], [2], [6]

Common questions about Activella and Kliovance

Is it progesterone?

It contains norethindrone acetate, a synthetic progestin, alongside estradiol. That is different from micronized progesterone. [1], [2] Molecular identity, progestogen type and the formulation are different questions. This tablet combines the two named components in a fixed ratio, so its evidence and schedule belong to that complete product. Separate estradiol and micronized progesterone permit a different prescribing plan, not an automatic tablet substitution. See the comparison. [1], [2]

Is every Activella strength labeled for vaginal atrophy?

The US vaginal-atrophy instruction uses 1 mg estradiol/0.5 mg norethindrone acetate. Check the indication, not only the brand. [1] A different strength may share the brand while having different labeled uses. If local symptoms are the main problem, discuss the exact goal and whether a local option is appropriate rather than assume every systemic tablet row applies. The whole prescription and personal eligibility still need review. See indications and benefits. [1]

Can two low-strength tablets replace one higher-strength tablet?

Their component ratios differ. Do not calculate a self-substitution; use the named complete prescription. [1] Matching only the estradiol total can leave a different progestin amount. A fixed combination changes both components together, and its protection evidence should not be transferred to an improvised ratio. Ask the pharmacist or prescriber about the actual supplied product and any authorized change. See the complete component rows. [1]

Should I add a week off?

The checked regimens are continuous combinations, not an estrogen-only cyclic schedule. [1], [2] Continuous use means both components are taken under the product’s daily plan, without borrowing the off interval of another hormone formulation. Missed-tablet and switching instructions also differ between the US and UK products. Ask about the exact pack if the routine is difficult. See daily use and switches. [1], [2] Bleeding also needs its own assessment.

Does included progestin eliminate all endometrial risk?

No. Protection belongs to the full regimen, and persistent or concerning bleeding still needs assessment. [1], [2], [3] Tell the clinician about the actual tablet, missed treatment and timing of bleeding. Included progestin is not a reason to ignore new symptoms or assume that added estrogen would receive sufficient opposition. The assessment should address the whole regimen and clinical pattern. See monitoring and bleeding. [1], [2], [3]

Is it contraception?

These checked indications are menopausal, not contraceptive. Address pregnancy prevention separately when relevant. [1], [2], [3] Its progestin contribution has a role in the menopausal combination without establishing contraceptive efficacy. A current contraceptive method can also change bleeding, so discuss both parts rather than infer pregnancy protection from a missed period. Do not add a combined pill independently. See the treatment goals. [1], [2], [3] Keep the supplied instructions available.

Were all warnings removed in 2026?

No blanket Activella update was verified; its retrieved revision remains November 2023. The first-six announcement concerned named other products. [1], [5] The distinction concerns the actual approved label, not whether a hormone is natural or synthetic. Ordinary precautions and contraindications still matter when evaluating a complete systemic regimen. Check later package information at the pharmacy, and do not apply another named product’s revision as this one’s status. See risks and regulatory scope. [1], [5]

Glossary

Definitions for interpreting the product, calendar and limitations.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Fixed combination

One dosage form contains both hormones; changing it changes both components.

Estradiol

The estrogen in these named menopause combinations.

Norethindrone / norethisterone acetate

The synthetic progestin in Activella and Kliovance.

CYP3A4

A metabolic enzyme affected by inducing or inhibiting medicines.

How was this guide researched?

Named full labels define calendars, indications and risks. Marketing records do not prove stock; guidelines inform care without changing authorization. Public accounts remain separate from clinical evidence. Sources identify document revision and access.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides